Emergence of rifampicin resistance in methicillin-resistant Staphylococcus aureus in tuberculosis wards

Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy
Jun-Ichiro SekiguchiTeruo Kirikae

Abstract

To assess whether the occurrence of rifampicin (RFP) resistance in methicillin-resistant Staphylococcus aureus (MRSA) is related to treatment of tuberculosis, we determined the RFP susceptibility of MRSA isolates obtained from tuberculosis patients and screened for mutation(s) in the rpoB gene of these isolates. The MICs of RFP for 84 MRSA isolates obtained from two hospitals in Japan were determined. DNA was sequenced in the region 1318-1602 nucleotides (nt) of the rpoB gene, which includes RFP resistance-determining clusters I (1384-1464 nt, 462-488 amino acids). The majority of MRSA isolates from tuberculosis wards, i.e., 48 of 51 (94%) [33 of 34 in a Tokyo hospital (97%) and 15 of 17 in a Chubu hospital (88%)], were resistant to RFP. Meanwhile, no isolates of 33 from the other wards were resistant to RFP. All RFP-resistant MRSA isolates had a mutation(s), including novel mutation(s) such as Val453-->AEPhe, Asp471-->AEAsn, and Ile527-->AELeu, in rpoB. An emergence of RFP-resistant MRSAs in tuberculosis wards in Japan was strongly suggested.

References

Jul 1, 1983·Reviews of Infectious Diseases·W Wehrli
Feb 7, 2001·The Journal of Antimicrobial Chemotherapy·T WichelhausB Böddinghaus
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·Thomas A WichelhausAlbrecht Ludwig
May 1, 2004·The Journal of Antimicrobial Chemotherapy·Elizabeth S R Darley, Alasdair P MacGowan
Jun 1, 1997·International Journal of Antimicrobial Agents·F J Schmitz, M E Jones

❮ Previous
Next ❯

Citations

Aug 22, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B HellmarkM Unemo
Mar 30, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Damon P Eisen, Justin S Denholm
Sep 26, 2012·Antimicrobial Agents and Chemotherapy·Aashish SrivastavaRichard H Ebright
Jun 26, 2009·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Devdatta Suhas NeogiPhani Madhuri Vonnum
Nov 4, 2008·The Journal of Bone and Joint Surgery. British Volume·D S NeogiS Rastogi
Oct 14, 2020·Antimicrobial Agents and Chemotherapy·Daniel G LloydEdward J Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.